These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 26343583

  • 21. Cross-Species Comparison of the Pan-RAF Inhibitor LY3009120's Anti-Tumor Effects in Equine, Canine, and Human Malignant Melanoma Cell Lines.
    Gao Y, Packeiser EM, Wendt S, Sekora A, Cavalleri JV, Pratscher B, Alammar M, Hühns M, Brenig B, Junghanss C, Nolte I, Murua Escobar H.
    Genes (Basel); 2024 Feb 03; 15(2):. PubMed ID: 38397192
    [Abstract] [Full Text] [Related]

  • 22. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
    Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggini M, Del Bufalo D, Cognetti F, Milella M, Ciuffreda L.
    J Exp Clin Cancer Res; 2018 Jul 09; 37(1):140. PubMed ID: 29986755
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
    Wei WJ, Sun ZK, Shen CT, Song HJ, Zhang XY, Qiu ZL, Luo QY.
    Theranostics; 2017 Jul 09; 7(4):987-1001. PubMed ID: 28382170
    [Abstract] [Full Text] [Related]

  • 25. Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations.
    Yao YM, Donoho GP, Iversen PW, Zhang Y, Van Horn RD, Forest A, Novosiadly RD, Webster YW, Ebert P, Bray S, Ting JC, Aggarwal A, Henry JR, Tiu RV, Plowman GD, Peng SB.
    Clin Cancer Res; 2017 Sep 15; 23(18):5547-5560. PubMed ID: 28611205
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.
    Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, Saborowski M, Kastenhuber E, Fellmann C, Ohara K, Morikami K, Miura T, Lukacs C, Ishii N, Lowe S, Rosen N.
    Cancer Cell; 2014 May 12; 25(5):697-710. PubMed ID: 24746704
    [Abstract] [Full Text] [Related]

  • 29. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling.
    Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N.
    Nat Med; 2019 Feb 12; 25(2):284-291. PubMed ID: 30559419
    [Abstract] [Full Text] [Related]

  • 30. Analyses of the oncogenic BRAFD594G variant reveal a kinase-independent function of BRAF in activating MAPK signaling.
    Cope NJ, Novak B, Liu Z, Cavallo M, Gunderwala AY, Connolly M, Wang Z.
    J Biol Chem; 2020 Feb 21; 295(8):2407-2420. PubMed ID: 31929109
    [Abstract] [Full Text] [Related]

  • 31. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Fritsche-Guenther R, Witzel F, Kempa S, Brummer T, Sers C, Blüthgen N.
    Oncotarget; 2016 Feb 16; 7(7):7960-9. PubMed ID: 26799289
    [Abstract] [Full Text] [Related]

  • 32. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
    Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J.
    Cancer Res; 2008 Jun 15; 68(12):4853-61. PubMed ID: 18559533
    [Abstract] [Full Text] [Related]

  • 33. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
    Jain P, Fierst TM, Han HJ, Smith TE, Vakil A, Storm PB, Resnick AC, Waanders AJ.
    Oncogene; 2017 Nov 09; 36(45):6348-6358. PubMed ID: 28806393
    [Abstract] [Full Text] [Related]

  • 34. Structure and RAF family kinase isoform selectivity of type II RAF inhibitors tovorafenib and naporafenib.
    Tkacik E, Li K, Gonzalez-Del Pino G, Ha BH, Vinals J, Park E, Beyett TS, Eck MJ.
    J Biol Chem; 2023 May 09; 299(5):104634. PubMed ID: 36963492
    [Abstract] [Full Text] [Related]

  • 35. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR, Cowley GS, Wagner S, Luo F, Root DE, Garraway LA.
    Mol Cancer Ther; 2015 Dec 09; 14(12):2700-11. PubMed ID: 26351322
    [Abstract] [Full Text] [Related]

  • 36. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH, Lee SE, Kim DW, Ryu MJ, Kim SJ, Kim SJ, Kim YK, Park JH, Kweon GR, Kim JM, Lee JU, De Falco V, Jo YS, Shong M.
    J Clin Endocrinol Metab; 2011 Jan 09; 96(1):E19-30. PubMed ID: 20926530
    [Abstract] [Full Text] [Related]

  • 37. Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors.
    Yen I, Shanahan F, Merchant M, Orr C, Hunsaker T, Durk M, La H, Zhang X, Martin SE, Lin E, Chan J, Yu Y, Amin D, Neve RM, Gustafson A, Venkatanarayan A, Foster SA, Rudolph J, Klijn C, Malek S.
    Cancer Cell; 2018 Oct 08; 34(4):611-625.e7. PubMed ID: 30300582
    [Abstract] [Full Text] [Related]

  • 38. Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers.
    Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H.
    Clin Cancer Res; 2018 Mar 01; 24(5):1090-1102. PubMed ID: 29196297
    [Abstract] [Full Text] [Related]

  • 39. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C, Estrada C, Barbotin C, Larcher M, Garancher A, Leloup J, Beermann F, Baccarini M, Pouponnot C, Larue L, Eychène A, Druillennec S.
    Nat Commun; 2017 May 12; 8():15262. PubMed ID: 28497782
    [Abstract] [Full Text] [Related]

  • 40. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
    Zhang Q, Wang J, Wang F, Chen X, He Y, You Q, Zhou H.
    Chem Biol Drug Des; 2014 Jan 12; 83(1):27-36. PubMed ID: 24164966
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.